141 related articles for article (PubMed ID: 21861128)
1. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
Ramírez J; Wu K; Janisch L; Karrison T; House LK; Innocenti F; Cohen EE; Ratain MJ
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1629-32. PubMed ID: 21861128
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Villalona-Calero M; Schaaf L; Phillips G; Otterson G; Panico K; Duan W; Kleiber B; Shah M; Young D; Wu WH; Kuhn J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):23-33. PubMed ID: 16685529
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
[TBL] [Abstract][Full Text] [Related]
5. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH
Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic pathway analysis of irinotecan.
Rosner GL; Panetta JC; Innocenti F; Ratain MJ
Clin Pharmacol Ther; 2008 Sep; 84(3):393-402. PubMed ID: 18418374
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Kuppens IE; Dansin E; Boot H; Feger C; Assadourian S; Bonneterre ME; Beijnen JH; Schellens JH; Bonneterre J
Clin Cancer Res; 2006 Jun; 12(12):3774-81. PubMed ID: 16778105
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
[TBL] [Abstract][Full Text] [Related]
12. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Argiris A; Kut V; Luong L; Avram MJ
Invest New Drugs; 2006 May; 24(3):203-12. PubMed ID: 16096702
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Venook AP; Enders Klein C; Fleming G; Hollis D; Leichman CG; Hohl R; Byrd J; Budman D; Villalona M; Marshall J; Rosner GL; Ramirez J; Kastrissios H; Ratain MJ
Ann Oncol; 2003 Dec; 14(12):1783-90. PubMed ID: 14630685
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Furman WL; Navid F; Daw NC; McCarville MB; McGregor LM; Spunt SL; Rodriguez-Galindo C; Panetta JC; Crews KR; Wu J; Gajjar AJ; Houghton PJ; Santana VM; Stewart CF
J Clin Oncol; 2009 Sep; 27(27):4599-604. PubMed ID: 19687340
[TBL] [Abstract][Full Text] [Related]
17. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
Engels FK; de Jong FA; Sparreboom A; Mathot RA; Loos WJ; Kitzen JJ; de Bruijn P; Verweij J; Mathijssen RH
Oncologist; 2007 Mar; 12(3):291-300. PubMed ID: 17405893
[TBL] [Abstract][Full Text] [Related]
18. Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Wang D; Braiteh F; Lee JJ; Denlinger CS; Shepard DR; Chaudhary A; Lin Y; Gao L; Asakiewicz C; Nasroulah F; LoRusso P
Cancer Chemother Pharmacol; 2016 Oct; 78(4):727-33. PubMed ID: 27507037
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Mross K; Steinbild S; Baas F; Reil M; Buss P; Mersmann S; Voliotis D; Schwartz B; Brendel E
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):618-9. PubMed ID: 14692719
[No Abstract] [Full Text] [Related]
20. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Raymond E; Fabbro M; Boige V; Rixe O; Frenay M; Vassal G; Faivre S; Sicard E; Germa C; Rodier JM; Vernillet L; Armand JP
Ann Oncol; 2003 Apr; 14(4):603-14. PubMed ID: 12649109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]